Obesity is an escalating epidemic, but an effective non-invasive therapy is still scarce. For obesity treatment, anorexigenic neuropeptides are promising tools, but their delivery from the periphery to the brain is complicated by their peptide character. In order to overcome this unfavorable fact, we have applied the lipidization of neuropeptide prolactin-releasing peptide (PrRP), whose strong anorexigenic effect was demonstrated. A palmitoylated analog of human PrRP (h palm-PrRP31) was injected in free-fed Wistar rats by three routes: subcutaneous (s.c.), intraperitoneal (i.p) (both 5 mg/kg) and intravenous (i.v.) (from 0.01 to 0.5 mg/kg). We found a circulating compound in the blood after all three applications with the highest concentration after i.v. administration. This corresponds to the effect on food intake, which was also strongest after i.v. injection. Moreover, this is in agreement with the fact that the expression of c-Fos in specific brain regions involved in food intake regulation was also highest after intravenous application. Pharmacokinetic data are further supported by results obtained from dynamic light scattering and CD spectroscopy. Human palm-PrRP31 analog showed a strong tendency to micellize, and formation of aggregates suggested lower availability after i.p. or s.c. application. We have demonstrated that palm-PrRP influenced food intake even in free fed rats. Not surprisingly, the maximal effect was achieved after the intravenous application even though two orders of magnitude lower dose was used compared to both two other applications. We believe that palm-PrRP could have a potential as an antiobesity drug when its s.c. application would be improved.

Department of Human and Clinical Pharmacology University of Veterinary Medicine Košice Slovak Republic

Institute of Organic Chemistry and Biochemistry Academy of Sciences of the Czech Republic Czech Republic

Institute of Physiology Academy of Sciences of the Czech Republic Prague Czech Republic

Laboratory of Functional Neuromorphology Institute of Experimental Endocrinology SAS Bratislava Slovak Republic

University of Chemistry and Technology Department of Analytical Chemistry Prague Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc17000808

003      

CZ-PrNML

005      

20170119112204.0

007      

ta

008      

170103s2016 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.peptides.2015.11.005 $2 doi

024    7_

$a 10.1016/j.peptides.2015.11.005 $2 doi

035    __

$a (PubMed)26643957

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Mikulášková, Barbora $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Czech Republic; Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic.

245    10

$a Effect of palmitoylated prolactin-releasing peptide on food intake and neural activation after different routes of peripheral administration in rats / $c B. Mikulášková, J. Zemenová, Z. Pirník, V. Pražienková, L. Bednárová, B. Železná, L. Maletínská, J. Kuneš,

520    9_

$a Obesity is an escalating epidemic, but an effective non-invasive therapy is still scarce. For obesity treatment, anorexigenic neuropeptides are promising tools, but their delivery from the periphery to the brain is complicated by their peptide character. In order to overcome this unfavorable fact, we have applied the lipidization of neuropeptide prolactin-releasing peptide (PrRP), whose strong anorexigenic effect was demonstrated. A palmitoylated analog of human PrRP (h palm-PrRP31) was injected in free-fed Wistar rats by three routes: subcutaneous (s.c.), intraperitoneal (i.p) (both 5 mg/kg) and intravenous (i.v.) (from 0.01 to 0.5 mg/kg). We found a circulating compound in the blood after all three applications with the highest concentration after i.v. administration. This corresponds to the effect on food intake, which was also strongest after i.v. injection. Moreover, this is in agreement with the fact that the expression of c-Fos in specific brain regions involved in food intake regulation was also highest after intravenous application. Pharmacokinetic data are further supported by results obtained from dynamic light scattering and CD spectroscopy. Human palm-PrRP31 analog showed a strong tendency to micellize, and formation of aggregates suggested lower availability after i.p. or s.c. application. We have demonstrated that palm-PrRP influenced food intake even in free fed rats. Not surprisingly, the maximal effect was achieved after the intravenous application even though two orders of magnitude lower dose was used compared to both two other applications. We believe that palm-PrRP could have a potential as an antiobesity drug when its s.c. application would be improved.

650    _2

$a zvířata $7 D000818

650    _2

$a látky proti obezitě $x aplikace a dávkování $x metabolismus $x farmakokinetika $7 D019440

650    _2

$a mozek $x metabolismus $7 D001921

650    _2

$a CHO buňky $7 D016466

650    _2

$a křečci praví $7 D006224

650    _2

$a Cricetulus $7 D003412

650    _2

$a preklinické hodnocení léčiv $7 D004353

650    _2

$a energetický příjem $x účinky léků $7 D002149

650    _2

$a lidé $7 D006801

650    _2

$a neurony $x účinky léků $x metabolismus $7 D009474

650    _2

$a obezita $x farmakoterapie $7 D009765

650    _2

$a peptidové fragmenty $x aplikace a dávkování $x metabolismus $x farmakokinetika $7 D010446

650    _2

$a hormon uvolňující prolaktin $x aplikace a dávkování $x analogy a deriváty $x metabolismus $x farmakokinetika $7 D056690

650    _2

$a vazba proteinů $7 D011485

650    _2

$a protoonkogenní proteiny c-fos $x metabolismus $7 D016760

650    _2

$a krysa rodu Rattus $7 D051381

650    _2

$a receptory spřažené s G-proteiny $x metabolismus $7 D043562

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Zemenová, Jana $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Czech Republic; University of Chemistry and Technology, Department of Analytical Chemistry, Prague, Czech Republic.

700    1_

$a Pirník, Zdenko $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Czech Republic; Laboratory of Functional Neuromorphology, Institute of Experimental Endocrinology, SAS, Bratislava, Slovak Republic; Department of Human and Clinical Pharmacology, University of Veterinary Medicine, Košice, Slovak Republic.

700    1_

$a Pražienková, Veronika $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Czech Republic.

700    1_

$a Bednárová, Lucie $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Czech Republic.

700    1_

$a Železná, Blanka $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Czech Republic.

700    1_

$a Maletínská, Lenka $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Czech Republic.

700    1_

$a Kuneš, Jaroslav $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Czech Republic; Institute of Physiology, Academy of Sciences of the Czech Republic, Prague, Czech Republic. Electronic address: kunes@biomed.cas.cz.

773    0_

$w MED00003749 $t Peptides $x 1873-5169 $g Roč. 75, č. - (2016), s. 109-17

856    41

$u https://pubmed.ncbi.nlm.nih.gov/26643957 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20170103 $b ABA008

991    __

$a 20170119112313 $b ABA008

999    __

$a ok $b bmc $g 1179948 $s 961375

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2016 $b 75 $c - $d 109-17 $e 20151128 $i 1873-5169 $m Peptides $n Peptides $x MED00003749

LZP    __

$a Pubmed-20170103